News

HansaBioMed Life Sciences and Finnish Red Cross Blood Service start a join effort forHansaBioMed Life Sciences and Finnish Red Cross Blood Service start a join effort fordeveloping next generation of Extracellular Vesicles from donated blood as referencematerial for researchers.

The new cooperation is set under the heads of agreement and is aimed to offer highly characterized andstandardized EV material for life science market to further accelerate the development of the EV applications indiagnostics and therapy.

Tallinn, Estonia, 18 January 2022.

HansaBioMed Life Sciences, is the oldest company entirely focused on the research and development of products inthe field extracellular vesicles (EVs). Today, HansaBioMed collaborates with various international groups, both Academicand Industrial, and participates in research projects aimed to implement the knowledge on the full potential of the EVs.Together with the research activities, HansaBioMed provides its customers with high quality of products dedicated to theExtracellular Vesicles and nanoparticle research.

“The current reference material available for the researchers in the field of Extracellular Vesicles requires constantimprovement and implementation. The collaboration with an experienced blood center, as the FRCBS, is aimed to achievea next generation of EVs from blood components, highly characterized and standardized both in preanalytical processingof the raw material and downstream EV purification. The final product will be an useful support for researchers workingon understanding of the potential of blood derived EVs” says Dr Paolo Guazzi COO, HansaBioMed.

Finnish Red Cross Blood Service (FRCBS) is the nationwide blood service provider in Finland and has been performingactive scientific research for more than 60 years. R&D activity can be divided into strategic focus areas: the effectivenessof the blood supply chain, new cell therapy treatments and the development of tissue transplants. FRCBS holds a solidposition in developing EV-based technologies with its partner network and is now exploring the possibilities to find partnersto manufacture EVs isolated from blood components such as erythrocytes, platelets and plasma.

“Our mission is to create potential for saving lives. We want to be in a forefront producing reliable material and scientificknowledge to explore the biomedical potential of blood EVs. We have developed isolation, purification and functionalcharacterization of extracellular vesicles from blood. Together with our partners in national EV consortium (EVE), FRCBShas reached its set goals and is ready to take the step towards EV production. For this step we need a partner that we cantrust on quality when moving forward. For us the obvious choice was HansaBioMed” says Dr Saara Laitinen, R&D managerat FRCBS and the leader of the country’s National EV Consortium.

HansaBioMed Life Sciences contact details:

Paolo Guazzi, Chief Operating Officer

This email address is being protected from spambots. You need JavaScript enabled to view it.

+372 6561996

Finnish red Cross Blood Service (FRCBS) contact details:

Saara Laitinen, R&D manager

This email address is being protected from spambots. You need JavaScript enabled to view it.

+358 29-300 1695

FLuoEVs: Purified EVs expressing Fluorescent proteins (lyophilized)

FLuoEVs are stably-fluorescent EVs expressing the fluorescent protein EGFP (green) BFP (blue) or mCherry (Red).

FLuoEVs are extracellular vesicles purified by combination of Tangential Flow Filtration (TFF) and Size Exclusion Chromatography (SEC) from cells engineered in order to express the fluorescent proteins as fusion protein with the tetraspanin CD9, CD63 or CD81.

FLuoEVs are currently available from HEK293 Cells, expressing EGFP (check the FluoEVs availability). On customer request, they can be produced from other cell lines and with fluorescent proteins mCherry (red) and BFP (Blue). For information write at: This email address is being protected from spambots. You need JavaScript enabled to view it.

A, B, C: Transfected cells expressing EGFP as fusion protein with CD9, CD81, CD63. D: Purified EVs expressing EGFP.

FLUO-EVs demonstrated high stability of the fluorophores, and several advantages over the lipidic dyes, widely used for the EV labelling, including higher percentage of fluorescent particles.

Moreover, all the fluorescent particles are originated from the parental cells, avoiding artifacts derived from the presence of dye micelles or non-specifically labelled lipidic particles (lipoproteins).

APPLICATIONS: FLuoEVs can be used for cell spike-in experiment and in vitro tracking studies, and as positive control for EV analysis, being compatible with the most common method of analysis (Fluorescence NTA, Flow cytometry, microplate fluorescence reading) and analyzers (Particle Metrix instruments, Nanoanlyzer NanoFCM, etc).

E: Comparison of FluoEVs expressing EGFP and EVs labeled with membrane dye Bodipy, analyzed by F-NTA with Zetaview analyzer (Particle Metrix). F: FluoEVs analyzed by Nanoanalyser NanoFCM.

Working with Plant EVs

Plant EVs, called also plant EV-like nanoparticles (ELNs), are attracting interest from researchers in academic sector, but also from the nutraceutical and the cosmetic industry. Indeed, plant EVs, such as the EV produced by mammalian cells, reflect the properties of the parental cells, can be purified from the plant leaves, stems, or juice, easily sterilized by filtration, and long-term stored. We started studying and working with extracellular vesicles from plant two years ago, in the context of a research project aimed to evaluate the particles produced by plants, in particular from Estonian origin, as potential source of regenerative and protective properties for skincare. In this period, we have developed expertise and methods for the purification and the characterization of vesicles from different plants, including rhizomes (ginger, ginseng), tubers (potato), Allioideae (garlic, onion), Cruciferae (cabbage family) and plant juices (coconut water, pineapple juice, orange and lemon juice). Our current workflow includes the preparation of the plant extract by plant juicer, the EV purification by Tangential Flow Filtration (TFF) or combination of TFF and Size Exclusion Chromatography. Among the particle analysis we can perform NTA, phenotyping by detecting the marker TET8, morphology analysis by Transmission Electron Microscopy.

Require more information or get a quote at: This email address is being protected from spambots. You need JavaScript enabled to view it.